EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma

Fei Ya Lai, Rachel Clarke, Patrick Cooper, John Stokes, Paula Calvert

Case Reports in Oncology · 16.10.2023 · 16 (1) · 1156-1165

DOI: 10.1159/000533759 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 16.10.2023. Verfasst von Fei Ya Lai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, University Hospital Waterford, Waterford, Ireland. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer. Surgery is usually curative; however, some locally advanced or metastatic CSCC may be unresectable. Current novel therapeutic options with immune checkpoint inhibition (ICI) of programmed-death receptor 1 (PD-1) such as cemiplimab and nivolumab have demonstrated promising and sustained results with good tolerability in patients with CSCC. This study looks at 2 cases of CSCC treated with cemiplimab and nivolumab, respectively, demonstrating dramatic response within 2 cycles with significant reduction in tumour size and minimal toxicities or adverse outcomes reported. Immunotherapy has shown positive results as an effective treatment option for unresectable, recurrent, or metastatic CSCC. It is currently approved for use in the USA and Europe.

Schlagwörter

Stichwörter der Autor:innen

Cutaneous oncologyCutaneous squamous cell carcinomaDermatologyImmune checkpoint inhibitorsImmunotherapyImmunotoxicitiesMetastatic cutaneous squamous cell carcinoma

Autor:innen und Institutionen

  • Oncology Department, University Hospital Waterford, Waterford, Ireland.
  • Radiology Department, University Hospital Waterford, Waterford, Ireland.
  • Ophthalmology Department, University Hospital Waterford, Waterford, Ireland.

Zitieren

APA

Lai, F. Y., Clarke, R., Cooper, P., Stokes, J., & Calvert, P. (2023). Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Case Reports in Oncology, 16(1), 1156-1165. https://doi.org/10.1159/000533759

Vancouver

Lai FY, Clarke R, Cooper P, Stokes J, Calvert P. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Case Reports in Oncology. 2023;16(1):1156-1165. doi:10.1159/000533759

BibTeX
@article{Lai2023,
  author = {Lai, Fei Ya and Clarke, Rachel and Cooper, Patrick and Stokes, John and Calvert, Paula},
  title = {Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma},
  journal = {Case Reports in Oncology},
  year = {2023},
  volume = {16},
  number = {1},
  pages = {1156--1165},
  doi = {10.1159/000533759}
}
Kostenlos starten →